Skip to content
    GERN
    Earnings call· Jun 2026(Q2 FY26)

    GERON Q2 FY26 earnings call GERN

    Aug 5, 2026 Source

    Executive summary

    Geron Q2 FY26 — Strong RYTELO Revenue Growth and Pipeline Progress

    Geron delivered a strong second quarter, driven by robust RYTELO net revenue growth and disciplined financial management. The company is expanding RYTELO's reach in the US, exploring European commercialization strategies, and advancing its Phase III IMPACT MF program. Management anticipates full-year net revenue to be at the mid-to-high end of its guidance range, reflecting confidence in its commercial execution and strategic priorities.

    Highlights

    5

    • Net revenue increased 17% year-over-year and 11% quarter-over-quarter to $57.5 million.

    • First half 2026 net revenue grew by approximately 24% compared to the same period a year ago.

    • RYTELO demand grew 5% quarter-over-quarter, with an 8% increase in prescribing accounts to approximately 1,575 since launch.

    • Total operating expenses decreased by 4% in H1 2026 compared to H1 2025, while net revenue increased 24%.

    • Ended Q2 FY26 with a strong cash position of $327 million.

    Concerns

    2

    • Gross to net deductions increased to 20.7% for Q2 FY26, compared to 15.3% for Q2 FY25.

    • Evaluating a modification to the event threshold for the interim analysis of the Phase III IMPACT MF trial, though projected timelines remain unchanged.

    Guidance & targets

    7
    CategoryTargetConfidence
    RYTELO net product revenue
    Mid- to high end of $220 million to $240 million
    high materiality
    High
    Total operating expenses
    $230 million to $240 million
    medium materiality
    High
    R&D expenses
    Continued investment in CMC and clinical development programs with lower employee costs
    low materiality
    Medium
    SG&A expenses
    Continued investment in RYTELO commercialization strategy and flat G&A spend
    low materiality
    Medium
    Gross to net deductions
    Low to mid-20s
    medium materiality
    High
    IMPACT MF trial final overall survival analysis
    Progression to final overall survival analysis in the second half of 2028
    high materiality
    High
    European commercialization plans
    Share plans before year-end
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    Hematology (RYTELO)
    Strong net revenue growth driven by continued expansion of awareness and education among healthcare professionals, with a focus on identifying appropriate second-line patients for low-risk MDS. Growth is predominantly driven by community accounts.
    RYTELO net revenue: $57.5 millionRYTELO demand growth QoQ: 5%Prescribing accounts: 1,575Prescribing accounts increase: 8%
    		$57.5 million17%11%—

    Operational metrics

    7
    Total operating expenses
    decreased by 4%vs H1 FY25
    H1 FY26

    Reflects financial discipline while net revenue increased 24%.

    Gross to net deductions
    20.7%vs 15.3% in Q2 FY25
    Q2 FY26

    Expected to be in the low to mid-20s for the remainder of 2026.

    R&D expenses
    $22 millionvs $21.7 million in Q2 FY25
    Q2 FY26

    Continued investment in CMC and clinical development programs.

    SG&A expenses
    $38.9 millionvs $38.6 million in Q2 FY25
    Q2 FY26

    Reflects continued investment in RYTELO commercialization strategy.

    Cash, cash equivalents, restricted cash and marketable securities
    $327 millionvs $341 million as of March 31, 2026
    as of June 30, 2026

    Provides flexibility to fund growth from current operations.

    First and second line patient starts
    34%
    rolling 12-month basis

    Indicates patient adoption trends for RYTELO.

    Eligible patients in U.S.
    around 8,000
    current

    Represents a significant opportunity for RYTELO.

    Industry KPIs

    5
    MetricValueDetails
    Launch access metrics1,575accounts
    Pipeline read out calendarH2 2028
    Product franchise net sales$57.5 millionUSD
    Prescription volume new starts34%%
    Clinical trial efficacy safety dataConsistent with Phase III IMerge trial

    Deals & partnerships

    1
    TamaraAppointment of Chief Business Officer

    Tamara brings deep business development experience and a proven track record of identifying and executing strategic growth opportunities. This appointment reflects Geron's commitment to maximizing the value of its current portfolio and building a leading hematology company.

    Risks & headwinds

    3
    Increased gross to net deductionsQ2 FY26, expected low to mid-20s for remainder of 2026

    20.7% for Q2 FY26, up from 15.3% in Q2 FY25

    Mitigation: Management is comfortable with the projection and does not expect significant spikes or decreases in the back half of the year.

    Potential modification to event threshold for IMPACT MF interim analysisH1 FY26 discussions, projected timelines for final OS analysis remain H2 2028

    Not quantified, involves discussions with regulatory authorities

    Mitigation: Proactive engagement with regulatory authorities to ensure adequacy for registration; does not change overall trial design.

    MFN (Most Favored Nation) dynamic impacting European commercial strategyOngoing, with plans to share European commercialization strategy before year-end

    Not quantified, but noted as evolving and being closely monitored

    Mitigation: Engaging with payers and medical experts, evaluating optimal ways to help patients while maintaining pricing integrity; strategy may include partnerships.

    What to watch in Q3 FY26

    4

    European Commercialization Plans for RYTELO

    Before year-end
    CurrentExploring gated commercial strategies
    TargetAnnouncement of specific plans

    Why it matters

    Will define the strategy for expanding RYTELO's reach to a significant patient population outside the U.S. and potential revenue streams.

    We expect to share our European commercialization plans before year-end, as previously stated.

    Q&A highlights

    4

    How might seasonality impact RYTELO sales in the second half of the year, and will commercial efforts offset it?

    Management does not expect significant spikes or decreases due to seasonality in the second half of the year. They anticipate consistent quarter-over-quarter growth, supported by disciplined financial and commercial teams, and are comfortable with gross-to-net projections in the low to mid-20s.

    “I mean, Tara, we continue to manage our inventory within the range of 2 to 4 weeks. And as I've guided that we're very comfortable with the gross to net projection in low to mid-20s. So we don't expect a significant spikes or decreases in the back half of the year.”

    asked by Tara Bancroft · answered by Michelle Robertson

    2 min read5 chapters

    Detailed Narrative

    01

    Commercial Performance and Strategy for RYTELO

    Geron reported strong Q2 FY26 net revenue of $57.5 million for RYTELO, marking a 17% year-over-year and 11% quarter-over-quarter increase. The company's refocused commercial strategy is gaining traction, evidenced by a 5% quarter-over-quarter demand growth and an 8% increase in prescribing accounts, now totaling approximately 1,575. The strategy prioritizes high-volume community treatment centers and identifying appropriate second-line low-risk MDS patients earlier in their treatment journey, targeting an estimated 8,000 eligible patients in the U.S.

    02

    Financial Discipline and Capital Allocation

    The company demonstrated financial discipline, with total operating expenses decreasing by 4% in the first half of FY26 compared to the same period in FY25, while net revenue grew 24%. Geron ended Q2 FY26 with a robust cash position of $327 million in cash, cash equivalents, restricted cash, and marketable securities. This financial strength provides flexibility to continue investing in the commercial business, advance scientific programs, and evaluate opportunistic innovation.

    03

    IMPACT MF Trial Regulatory Engagement

    Geron is proactively engaging with regulatory authorities and external experts regarding the Phase III IMPACT MF trial in relapsed/refractory myelofibrosis. The discussions focus on ensuring the interim analysis design is adequate to support registration, should the Data Monitoring Committee recommend unblinding for positive efficacy. The company is evaluating a modification to the event threshold for this interim analysis, though the projected timelines for the final overall survival analysis in the second half of 2028 remain unchanged.

    04

    European Expansion Plans for RYTELO

    Recognizing a significant unmet need for patients with low-risk MDS in Europe, Geron is exploring gated commercial strategies to bring RYTELO to appropriate patients while maintaining pricing integrity. The company is monitoring the evolving MFN (Most Favored Nation) dynamic and expects to share its European commercialization plans before year-end, as previously stated, potentially including partnership conversations.

    05

    Real-World Evidence Reinforces RYTELO Profile

    At the European Hematology Association (EHA) meeting, Geron presented the first real-world evidence study of RYTELO in low-risk MDS. This investigator-sponsored study, conducted with Market Cancer Center, showed findings generally consistent with the Phase III IMerge trials. The data reinforced RYTELO's safety, efficacy, and tolerability profile in a broader real-world patient population and indicated a trend toward optimal management of cytopenias and improved responses when RYTELO was used within the first three lines of therapy.

    AI-generated summary of the company’s earnings call. Not investment advice.